However, silencing of mTOR enhanced the sensitivity of PC-3 cells to the growth-inhibitory effects of bardoxolone methyl, suggesting that Akt and mTOR are key molecular targets of bardoxolone methyl in prostate cancer cells. Here, MTOR is linked to prostate carcinoma.